Urine testing

federal-form.jpgEarlier this year, the Department of Health and Human Services (HHS) revised the Mandatory Guidelines for Federal Workplace Drug Testing Programs. The HHS guideline revisions will lead to the following changes:

  • Expanded Federal urine workplace drug testing to include four Schedule II drugs: hydrocodone, hydromorphone, oxycodone, and oxymorphone
  • Removed MDEA for confirmatory testing
  • Raised the lower pH cutoff from 3 to 4 to identify an adulterated specimen
  • Allowed a Medical Review Officer (MRO) to recommend the collection of an oral fluid specimen in certain situations, as permitted by agency policy

This week, the Office of Management and Budget (OMB) approved the revised Federal Custody and Control Form (CCF). This approval essentially links the forthcoming testing changes to the required paperwork that will accompany the testing specimens. HHS published a Q&A document to help clarify a number of the changes.

While the impact of these revised regulations is somewhat complex, here are a few key insights that you should be aware of at this time:

1. These changes only apply to Federal employee testing. If your company performs oral fluid, hair, instant, or non-DOT urine drug testing, these changes do not apply to your program.

2. At this time, you should not order new paper CCF forms. The new Federal form was approved earlier this week—on August 8, 2017. As such, the printing of new forms has not yet begun. The Federal forms you have on hand today are still valid and can be used without issue for another 10 months—until June 30, 2018.

**Update** On Tuesday, August 15, 2017, the Department of Transportation (DOT) published a notice in response to the HHS release from August 8, 2017. In this notice, they state that because the DOT’s final rule on synthetic opiates has yet to be issued, “…employers and their service agents are to continue using the ‘old’ CCF until further notice from DOT’s Office of Drug and Alcohol Policy and Compliance.”

3. The anticipated go-live date for the testing changes detailed in the bullet points above is October 1, 2017. This week’s announcement only pertains to Federal CCF forms, and was essentially published to give laboratories and other service providers the ability to cease production of the legacy form and to transition production to the new form.

4. There has never been a better time to switch to eCCF. You have better things to do than keeping tabs on changing form and panel regulations, ensuring you’re using the correct form at the proper time, and dealing with the expense and hassles of shipping and storing all of this paperwork. Our electronic CCF (eCCF) process helps bear the regulatory and administrative burden for you— the new, online form is scheduled to go live in our system on October 1. There’s no cost to use it, it’s available today for all specimen types and testing reasons, and it’s simple to use. In the time it’s taken you to read this article, you could have signed up and gotten started.

As your partner in drug testing and workplace safety, we are aware of the changes and are working diligently on your behalf to ready our laboratories, systems, and personnel. We are committed helping create a smooth and seamless transition as we collectively adapt to the regulatory obligations to which we’re bound.

As we do all of this, you should do three simple things:

  • Continue testing as usual. The effort at this point falls on the laboratory, not on you or your drug testing program. You do not need new forms at this time
  • Join the thousands of customers of all sizes and in all industries who have moved away from paper-based drug testing documentation and who are now processing millions of eCCFs each year

For more information about drug testing, visit our website or contact us online.

Revisions to Federal Workplace Drug Testing

by Nicole Jupe on February 10, 2017

On January 23, 2017, the U.S. Department of Health and Human Services (HHS) revised the Mandatory Guidelines for Federal Workplace Drug Testing Programs. More specifically, the notice expanded federal urine workplace drug testing to include four Schedule II drugs: hydrocodone, hydromorphone, oxycodone, and oxymorphone. The effective date for the revised Guidelines is October 1, 2017. The U.S. Department of Transportation (DOT) also published a notice of proposed rulemaking to amend 49 CFR Part 40 to harmonize with HHS to expand its federal drug testing panel. There is a 60-day comment period with a deadline of March 24, 2017 for these DOT proposed rules.

In addition to adding four Schedule II opioids to regulated drug testing programs, the notices included several minor changes: adding MDA as an initial test analyte and removing MDEA for confirmatory testing. The revised HHS Guidelines also raise the lower pH cutoff from 3 to 4 to identify an adulterated specimen and allow the Medical Review Officer (MRO) to recommend the collection of an oral fluid specimen in certain situations, as permitted by agency policy. The proposed DOT rules would also eliminate the requirement for employer blind specimen testing and updates some MRO training/re-certification requirements.

We wanted to answer some of your most common questions regarding this announcement.

  • When will the DOT require these Schedule II drugs as part of its panel?
    The public comments on the proposed DOT rules are due March 24, 2017. It is anticipated that the DOT will publish rules that are harmonized with HHS with an effective date of October 1, 2017. This timing would be dependent on the number and content of the comments as well as the regulatory process.
  • What will be the name of this drug test panel?
    Based on the past implementation of the August 16, 2010 (effective October 1, 2011) harmonized DOT rules that added additional analytes, the DOT still considered the test a “5‑panel” drug test. Until the final rules are published, the name of the revised drug test panel is unknown. However, Quest Diagnostics will utilize a new order code for this new drug test panel. All of our DOT ordering accounts will be automatically updated to this new order code and panel name on the effective date of the new rules.
  • Can I start testing our DOT employees now? What about non-regulated drug testing?
    No, because changes may still be made to DOT or other regulated drug testing until the effective date of their respective requirements. Non-regulated testing of prescription (“expanded”) opiates is already permitted in compliance with applicable state laws and regulations. In 216, approximately 19 percent of our non-regulated opiate drug testing currently includes these prescription opiates.

We work to continually refine our laboratory testing to comply with changing regulations and as part of our commitment to quality and scientific innovation. Stay up to date with this regulation and other industry news on our website, blog, and social media communities.

Read the HHS revised guidelines in the Federal Register

We encourage everyone to read the DOT Proposed Rules and comment.

View the Quest Diagnostics Drug Testing Index™ for urine testing positivity data.

For more information, contact your sales representative or contact us online.

Clarifying the New OSHA Post-Accident Drug Testing Regulations

February 3, 2017Drug Testing

New regulations issued by the Occupational Safety and Health Administration (OSHA) regarding Recording and Reporting Occupational Injuries and Illnesses became effective on December 1, 2016. The regulations prohibit employers from retaliating against employees for reporting workplace injuries and illnesses (OSHA 29 CFR 1904). Although drug and alcohol testing was not mentioned in the Final Rule […]

Read the full article →

Important Changes With eCCF

October 10, 2016Urine testing

The content below highlights a number of the changes you should expect as you prepare to make the transition to electronic custody and control forms, or eCCF, for Federal drug testing from Quest Diagnostics. One of the biggest changes is the use of the Specimen ID as the single, identifying number for all drug testing […]

Read the full article →

Combating Cheating in Urine Drug Testing

July 18, 2016Urine testing

At Quest Diagnostics, we take the issue of subversion of the drug testing process very seriously. We continue to be pioneers in specimen validity testing (SVT) – a screening to help ensure the integrity of the urine specimen and drug test. We first patented our screening technology for oxidizing adulterants in 2000 and testified before […]

Read the full article →

Detecting Drug Abuse Among Medical Professionals

July 6, 2016Urine testing

The challenges associated with opioid abuse can impact anyone regardless of gender, age, race, or job position. Perhaps surprisingly to some, that fact that some physicians struggle with substance abuse and addiction is not a new phenomenon. USA Today reported that more than 100,000 doctors, nurses, technicians and other healthcare professionals struggle with abuse or […]

Read the full article →

Fentanyl In the News

June 29, 2016Urine testing

Fentanyl is a powerful synthetic opioid that is similar to morphine but is 50 to 100 times more potent, according to the National Institute on Drug Abuse. Used to treat pain, it is categorized as a Schedule II drug and carries a “black box warning” from the Food and Drug Administration (FDA) to call attention […]

Read the full article →

Random Drug Testing Benefits Employers

June 15, 2016Drug Testing

Drug testing programs aim to prevent the hiring of drug-using applicants while deterring drug use among current employees. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), 21.4 percent of employed adults used illicit drugs within the past month. Results from the 2014 Quest Diagnostics Drug Testing Index™ (DTI) show that, in the general […]

Read the full article →

Drug Testing Needs Assessment

March 14, 2016Drug Testing

Employers are tasked with making important decisions about how best to keep their workplaces safe, productive and drug-free. An important component of creating and maintaining a drug-free workplace is having an effective drug testing program. And, while urine drug testing has been the standard for decades, there are now many other drug testing options available, […]

Read the full article →

Add Certainty with Specimen Validity Testing

December 18, 2015Urine testing

Urine drug testing is the most frequently used drug testing method and is trusted by government agencies and businesses to be accurate and scientifically sound for detecting a wide range of illicit and prescription drugs. It is the only specimen type approved for U.S. Department of Transportation (DOT) federally-regulated drug testing. While it is the […]

Read the full article →